What Zentalis Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 1 | 2 |
| Sells | 0 | 10 |
| Total trades | 2 | 19 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 4,344,727 | 11,204,400 |
| Disposed | 0 | 55,372 |
| Net activity | +4,344,727 | +11,149,028 |
Common stock only — 1 reported trade in the last 12 months is in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer | Sep 30 | Grant / award · A | +9,727 | $2.18 | +$21.2K | 43,059 |
| Walters Group | 10% owner | Aug 14 | Open-market buy · P | +4,335,000 | $3.50 | +$15.2M | 17,844,973 |
| Kariuki Enoch | Director | Jun 16 | Grant / award · A | +57,100 | — | — | 194,465 |
| Myers Scott Dunseth | Director | Jun 16 | Grant / award · A | +57,100 | — | — | 395,895 |
| Walker Luke Nathaniel | Director | Jun 16 | Grant / award · A | +57,100 | — | — | 201,384 |
| Skvarka Jan | Director | Jun 16 | Grant / award · A | +57,100 | — | — | 264,254 |
| Johnson David Michael | Director | Jun 16 | Grant / award · A | +57,100 | — | — | 307,521 |
| Campbell Shannon | Director | May 26 | Grant / award · A | +114,200 | — | — | 114,200 |
| Vultaggio Vincent | PAO and PFO | Feb 10 | Disclosed 10b5-1 sale · S | −6,894 | $2.42 | −$16.7K | 146,506 |
| Vultaggio Vincent | PAO and PFO | Feb 09 | Sale for tax withholding · S | −3,379 | $2.39 | −$8.09K | 153,400 |
| Eastland Julia Marie | CEO & President | Feb 09 | Sale for tax withholding · S | −889 | $2.39 | −$2.13K | 79,133 |
| Bruns Ingmar | Chief Medical Officer | Feb 09 | Sale for tax withholding · S | −335 | $2.39 | −$802 | 33,332 |
| Vultaggio Vincent | PAO and PFO | Feb 06 | Sale for tax withholding · S | −29,951 | $2.43 | −$72.8K | 156,779 |
| Eastland Julia Marie | CEO & President | Feb 06 | Sale for tax withholding · S | −7,866 | $2.43 | −$19.1K | 80,022 |
| Bruns Ingmar | Chief Medical Officer | Feb 06 | Sale for tax withholding · S | −2,962 | $2.43 | −$7.2K | 33,667 |
| Vultaggio Vincent | PAO and PFO | Feb 03 | Disclosed 10b5-1 sale · S | −556 | $2.52 | −$1.4K | 186,730 |
| Vultaggio Vincent | PAO and PFO | Feb 02 | Sale for tax withholding · S | −2,540 | $2.55 | −$6.48K | 187,286 |
| Walters Group | 10% owner | Dec 31 | Open-market buy · P | +6,459,973 | $1.20 | +$7.75M | 13,509,973 |
| Matrix Capital Management Company, Lp | 10% owner | Dec 15 | Open-market sale · S | −7,500,000 | $1.33 | −$9.98M | 6,459,973 |
| Myers Scott Dunseth | Director | Jun 17 | Grant / award · A | +57,603 | — | — | 338,795 |
Loading...
